All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Francesca Gay, University of Torino, Torino, IT, presents a risk analysis update from the FORTE trial of carfilzomib + lenalidomide + dexamethasone (KRd) with, or without, transplantation in patients with newly diagnosed multiple myeloma (NDMM). This interview was conducted during the 2019 ASCO meeting in Chicago, US. This analysis showed that KRd both with, and without, transplant was highly effective at inducing responses and minimal residual disease (MRD) negativity. Approximately 50% of high-risk patients treated with KRd (with or without) transplant achieved MRD negativity. Patients who were transplanted, achieved a higher rate of sustained MRD negativity at 1 year. Additionally, transplant was of more benefit in patients with high-risk disease, as it led to a reduced risk of early relapse (within 18 months from start of therapy).
FORTE trial: updated efficacy analysis by risk status
Subscribe to get the best content related to multiple myeloma delivered to your inbox